- Home
- PNNT vs CMRX Comparison
PNNT vs CMRX Comparison
Compare PNNT & CMRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PNNT
- CMRX
- Stock Information
- Founded
- PNNT 2007
- CMRX 2000
- Country
- PNNT United States
- CMRX United States
- Employees
- PNNT N/A
- CMRX N/A
- Industry
- PNNT Finance: Consumer Services
- CMRX Biotechnology: Pharmaceutical Preparations
- Sector
- PNNT Finance
- CMRX Health Care
- Exchange
- PNNT Nasdaq
- CMRX Nasdaq
- Market Cap
- PNNT 459.4M
- CMRX 394.1M
- IPO Year
- PNNT 2007
- CMRX 2013
- Fundamental
- Price
- PNNT $7.17
- CMRX $5.15
- Analyst Decision
- PNNT Hold
- CMRX Strong Buy
- Analyst Count
- PNNT 2
- CMRX 2
- Target Price
- PNNT $6.00
- CMRX $8.50
- AVG Volume (30 Days)
- PNNT 436.5K
- CMRX 1.7M
- Earning Date
- PNNT 02-10-2025
- CMRX 03-07-2025
- Dividend Yield
- PNNT 12.97%
- CMRX N/A
- EPS Growth
- PNNT 11.30
- CMRX N/A
- EPS
- PNNT 0.83
- CMRX N/A
- Revenue
- PNNT $143,689,000.00
- CMRX $159,000.00
- Revenue This Year
- PNNT N/A
- CMRX N/A
- Revenue Next Year
- PNNT N/A
- CMRX $1,690.28
- P/E Ratio
- PNNT $8.62
- CMRX N/A
- Revenue Growth
- PNNT N/A
- CMRX N/A
- 52 Week Low
- PNNT $6.43
- CMRX $0.75
- 52 Week High
- PNNT $8.04
- CMRX $5.53
- Technical
- Relative Strength Index (RSI)
- PNNT 54.56
- CMRX 76.25
- Support Level
- PNNT $7.10
- CMRX $3.94
- Resistance Level
- PNNT $7.25
- CMRX $5.53
- Average True Range (ATR)
- PNNT 0.09
- CMRX 0.30
- MACD
- PNNT 0.00
- CMRX 0.07
- Stochastic Oscillator
- PNNT 70.69
- CMRX 78.29
About PNNT PennantPark Investment Corporation
Pennant Park Investment Corp is a closed-end, non-diversified investment company. Its investment objective is to generate current income and capital appreciation also seeking to preserve capital through debt and equity investments. The company focuses on investing in United States middle-market companies that offer attractive risk-reward to investors and to create a diversified portfolio that includes senior secured debt, mezzanine debt, and equity investments. It generates majority of its revenue from interest and dividends received from investments made.
About CMRX Chimerix Inc.
Chimerix Inc. is a biopharmaceutical company based in the United States that engages in the research, development, and commercialization of medicines. Its portfolio includes treatment for acute myeloid leukemia (or AML) and antiviral treatment for smallpox. The company generates revenue through revenue related to non-refundable upfront fees, royalties and milestone payments earned under license agreements, also by royalty revenue related to sales of TEMBEXA made by Emergent after the Asset Sale. The company operates only in one business segment namely pharmaceuticals.